When the future of ADCs and bispecifics collide
What can we learn from the initial LBA abstract titles?
Why what we don't know might kill a few cancer programs
A look atfive recent developments and what we can learn from them
When the going gets tough, the tough get going...
Where we look at half a dozen emerging agents and put them through their paces
Our take on data from half a dozen key trials at ASCO GI24
Winners and losers at JPM24
Important lessons learned from failure
Spotting the winners and losers in the gastric cancer niche
From epigenetics to SHP2, a look at various upcoming presentations this month
From CAR-T cells to protein degradation
As we head into the long August Bank Holiday and Labor Day celebrations, I wanted to offer some…
Preview - Wwat to watch for at WCLC23
Continuing our coverage of the annual meeting of ASCO in Chicago I felt compelled to review the actual…
Some ASCO23 abstracts to watch out for and why
How can we overcome immune escape in relation to TIGIT therapies?
A deeper look at the ARC-7 TIGIT readout
10 early stage IO biotechs to watch out for
Five areas of early stage IO developments to watch out for
Six important factors to consider when looking at the SKYSCRAPER-01 TIGIT readout
Can you have your immune cake and eat it?
A careful look at the latest anti-TIGIT data
Several controversies abound in the CAR-T cell niche this year, plus what's coming next?
Sometimes we learn more from failure than we do from success
Update on the various runners and riders in the TIGIT niche
SITC 2021 Preview
A careful look at what we can learn from the Beigene anti-TIGIT data for ociperlimab
Do we need to target the adenosine fog as well as TIGIT in NSCLC?
Going beyond the obvious conclusion with anti-LAG3 therapy
Gems from the WCLC20 poster hall which may make an impact
Important developments on the GI cancer front to watch out for
Winners, losers and risers... who goes where in the final analysis?
Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds
A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer
A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.
What to watch out for at AACR20 - the first of our meeting previews is here!
A look at off Broadway abstracts on early new product development and scientific findings of interest
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
